Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development...

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.18
Views: 570

Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria

Dr Sexl speaks with ecancer at EHA 23 about findings implicating modulation of the JAK-STAT pathway in the transition of myelofibrosis to B cell lymphoma.

She describes the mixed signals of the disease transitioning from one to the other, and the existence of a hidden, amplified B cell clone which drives the aggressive lymphoma.

Dr Sexl recommends screening for this clonal population in patients eligible for JAK-STAT inhibition.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation